A retrospective, cohort study describing the frequency and clinical characteristics of endocrine immune-related adverse events in patients taking cancer immunomodulatory therapies
Latest Information Update: 19 Aug 2019
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 19 Aug 2019 New trial record